Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-experienced Hiv-1 Infected Patients

Next Previous
Trial Profile

An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-experienced Hiv-1 Infected Patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maraviroc (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms POEM
  • Sponsors Pfizer; ViiV Healthcare

Most Recent Events

  • 13 Mar 2019 Status changed from active, no longer recruiting to completed.
  • 28 Jun 2017 Planned End Date changed from 31 Oct 2018 to 26 Feb 2019.
  • 28 Jun 2017 Planned primary completion date changed from 31 Oct 2018 to 26 Feb 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top